Literature DB >> 4078726

Time course study of the effects of chronic nicotine infusion on drug response and brain receptors.

M J Marks, J A Stitzel, A C Collins.   

Abstract

The experiments reported here examined the time course of the development and loss of tolerance to nicotine as well as the time course for the up-regulation and return to basal levels of brain nicotinic receptors. Nicotine was administered by continuous i.v. infusion through cannulae implanted in the right jugular veins of DBA mice. Tolerance to the effects of nicotine on Y-maze activity and rears, body temperature and heart rate was seen accompanying the infusion of 4 mg/kg/hr of nicotine. Maximal tolerance was obtained in 4 days and was paralleled by increases in the number of brain nicotine binding sites. The binding of alpha-bungarotoxin was also increased by chronic nicotine treatment but increases in binding preceded the development of detectable tolerance to the challenge dose of nicotine. Chronic nicotine treatment had no effect on quinuclidinyl benzilate binding. Tolerance to the effects of nicotine was lost at different rates for the various tests in that base-line response was attained for the Y-maze activity and rearings test in 8 days, whereas 12 to 16 days were required to regain control response for the body temperature test. Tolerance for the heart rate test persisted throughout the 20-day withdrawal period. Brain nicotine binding sites had returned to control levels by 8 days after treatment whereas the alpha-bungarotoxin binding sites were at control levels at the earliest time of postinfusion testing (4 days). Brain quinuclidinyl benzilate binding sites were unaffected by nicotine treatment and did not change during the withdrawal period. The changes in nicotine binding in the various brain regions during the onset and offset experiments were virtually identical. These changes in binding correlated highly with the acquisition and loss of tolerance to the effects of nicotine on the Y-maze locomotor activity and body temperature tests. The correlations between changes in nicotine binding and the Y-maze rearings and the heart rate tests were lower but some association is suggested. Although changes in nicotine binding may explain some of the tolerance observed, other explanations for tolerance must be sought as well.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4078726

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  83 in total

1.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

3.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

Review 4.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

5.  The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation.

Authors:  Thomas J Gould; George S Portugal; Jessica M André; Matthew P Tadman; Michael J Marks; Justin W Kenney; Emre Yildirim; Michael Adoff
Journal:  Neuropharmacology       Date:  2012-01-21       Impact factor: 5.250

6.  An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification.

Authors:  M V Guseva; D M Hopkins; J R Pauly
Journal:  Pharmacol Biochem Behav       Date:  2006-06-06       Impact factor: 3.533

7.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 8.  Postsynaptic scaffolds for nicotinic receptors on neurons.

Authors:  Robert A Neff; David Gomez-Varela; Catarina C Fernandes; Darwin K Berg
Journal:  Acta Pharmacol Sin       Date:  2009-05-11       Impact factor: 6.150

9.  Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists.

Authors:  M Shoaib; M E Benwell; M T Akbar; I P Stolerman; D J Balfour
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

10.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.